Investigating how Trop-2 affects advanced prostate cancer treatment
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
['FUNDING_R01'] · UNIVERSITY OF WISCONSIN-MADISON · NIH-10873817
This study is looking at why some advanced prostate cancer treatments don't work as well for certain patients, especially those with a tough form of the disease, and it hopes to find new ways to help improve their treatment options.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WISCONSIN-MADISON (nih funded) |
| Locations | 1 site (MADISON, UNITED STATES) |
| Trial ID | NIH-10873817 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the molecular mechanisms behind treatment resistance in advanced prostate cancer, particularly in patients with metastatic castrate resistant prostate cancer (mCRPC). By examining the role of Trop-2 and other molecular factors, the study aims to identify new therapeutic strategies that could improve patient outcomes. The approach includes analyzing genomic and epigenomic changes in cancer cells to uncover potential vulnerabilities that can be targeted with new treatments. Patients may be involved in clinical trials that test these innovative therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castrate resistant prostate cancer who have limited treatment options.
Not a fit: Patients with early-stage prostate cancer or those who do not have metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival and quality of life for men with advanced prostate cancer.
How similar studies have performed: Previous research has shown promise in targeting molecular mechanisms in advanced prostate cancer, indicating potential for success with this approach.
Where this research is happening
MADISON, UNITED STATES
- UNIVERSITY OF WISCONSIN-MADISON — MADISON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LANG, JOSHUA MICHAEL — UNIVERSITY OF WISCONSIN-MADISON
- Study coordinator: LANG, JOSHUA MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Patient, Cancers